Eculizumab in the treatment of membranoproliferative glomerulonephritis.
A major shift in our understanding of the membranoproliferative glomerulonephritis (MPGN) lesion is the focus on which components of the complement pathway are involved in mediating renal injury. Hence, MPGN is no longer classified solely by ultrastructural findings on biopsy but instead divided into immune complex-mediated lesions versus complement-mediated lesions. This emphasis on complement, in turn, leads to interest in therapies that target complement as potential disease-modifying agents. Eculizumab, the first available anticomplement therapy, blocks at the level of C5 and has revolutionized the treatment of complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Whether this agent will work equally well for the far more heterogeneous complement-mediated MPGN lesions, also known as C3 glomerulopathy, remains unclear. To date, the experience and published data on using eculizumab in MPGN suggests this agent will work for some, but not all, patients with this pathologic lesion.
Department of Medicine, Division of Nephrology, Columbia University Medical Center, New York, N.Y., USA.
Andrew S
AS
Bomback
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome / Q000188:drug therapy / Q000276:immunology; D003176:Complement C3 / Q000276:immunology; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000276:immunology; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy / Q000276:immunology; D006801:Humans
D061067:Antibodies, Monoclonal, Humanized; D003176:Complement C3; C481642:eculizumab